{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:47:12Z","timestamp":1790790432525,"version":"4.1.0"},"reference-count":52,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Austrian Science Fund","award":["P35951"],"award-info":[{"award-number":["P35951"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,11,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Azole antifungals remain the \u201cgold standard\u201d therapy for invasive aspergillosis. The world-wide emergence of isolates resistant to this drug class, however, developed into a steadily increasing threat to human health over the past years. In\n            <jats:italic>Aspergillus fumigatus<\/jats:italic>\n            , major mechanisms of resistance involve increased expression of\n            <jats:italic>cyp51A<\/jats:italic>\n            encoding one of two isoenzymes targeted by azoles. Yet, the level of resistance caused by\n            <jats:italic>cyp51A<\/jats:italic>\n            upregulation\n            <jats:italic>,<\/jats:italic>\n            driven by either clinically relevant tandem repeat mutations within its promoter or the use of high expressing heterologous promoters, is limited. Cytochrome P450 enzymes such as Cyp51A rely on redox partners that provide electrons for their activity.\n            <jats:italic>A. fumigatus<\/jats:italic>\n            harbors several genes encoding putative candidate proteins including two paralogous cytochrome P450 reductases, CprA and CprB, and the cytochrome\n            <jats:italic>b<\/jats:italic>\n            <jats:sub>5<\/jats:sub>\n            CybE. In this work, we investigated the contribution of each\n            <jats:italic>cprA<\/jats:italic>\n            ,\n            <jats:italic>cprB,<\/jats:italic>\n            and\n            <jats:italic>cybE<\/jats:italic>\n            overexpression to\n            <jats:italic>cyp51A<\/jats:italic>\n            -mediated resistance to different medical and agricultural azoles. Using the bidirectional promoter\n            <jats:italic>PxylP<\/jats:italic>\n            , we conditionally expressed these genes in combination with\n            <jats:italic>cyp51A<\/jats:italic>\n            , revealing\n            <jats:italic>cprA<\/jats:italic>\n            as the main limiting factor. Similar to this approach, we overexpressed\n            <jats:italic>cprA<\/jats:italic>\n            in an azole-resistant background strain carrying a\n            <jats:italic>cyp51A<\/jats:italic>\n            allele with TR34 in its promoter, which led to a further increase in its resistance. Employing sterol measurements, we demonstrate an enhanced eburicol turnover during upregulation of either\n            <jats:italic>cprA<\/jats:italic>\n            or\n            <jats:italic>cyp51A<\/jats:italic>\n            , which was even more pronounced during their simultaneous overexpression. In summary, our work suggests that mutations leading to increased Cyp51A activity through increased electron supply could be key factors that elevate azole resistance.\n          <\/jats:p>","DOI":"10.1128\/aac.00918-23","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:01:15Z","timestamp":1696942875000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["The cytochrome P450 reductase CprA is a rate-limiting factor for Cyp51A-mediated azole resistance in\n            <i>Aspergillus fumigatus<\/i>"],"prefix":"10.1128","volume":"67","author":[{"given":"Alexander","family":"K\u00fchbacher","sequence":"first","affiliation":[{"name":"Institute of Molecular Biology, Biocenter, Medical University of Innsbruck , Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Merschak","sequence":"additional","affiliation":[{"name":"Institute of Molecular Biology, Biocenter, Medical University of Innsbruck , Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-9878","authenticated-orcid":true,"given":"Hubertus","family":"Haas","sequence":"additional","affiliation":[{"name":"Institute of Molecular Biology, Biocenter, Medical University of Innsbruck , Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Liebl","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians Universit\u00e4t M\u00fcnchen , Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians Universit\u00e4t M\u00fcnchen , Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9257-8648","authenticated-orcid":true,"given":"Fabio","family":"Gsaller","sequence":"additional","affiliation":[{"name":"Institute of Molecular Biology, Biocenter, Medical University of Innsbruck , Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.002"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw444"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2023.2172264"},{"key":"e_1_3_3_5_2","unstructured":"World Health Organization\n. 2022. Fungal priority pathogens list to guide research development and public health action. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240060241"},{"key":"e_1_3_3_6_2","unstructured":"Centers for Disease Control and Prevention\n. 2018. Antibiotic resistance threats in the United States. Available from: https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fbr.2020.10.003"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2015.0460"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/1462-2920.15274"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0714-4"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000729"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.00092"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fgb.2015.06.001"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fgb.2011.08.002"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit320"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01092-06"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780802545600"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2503.180297"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006106"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006096"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02563-18"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01209-22"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00702-22"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00437-19"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1006\/fgbi.1997.1021"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-5793(99)01548-3"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470123065.ch2"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-291x(89)80139-1"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(94)90366-2"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1039\/c7mt00110j"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.730297"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2507.181625"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-1656(96)01403-4"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01131-18"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.66.11.4810-4816.2000"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mec.2022.e00214"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00230-20"},{"key":"e_1_3_3_38_2","volume-title":"EUCAST definitive document EDef 9.4: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds EDef 9.4","author":"Guinea J","year":"2022","unstructured":"Guinea J , Meletiadis J , Arikan-Akdagli S , Muehlethaler K , Kahlmeter G , Arendrup MC , Eucast A . 2022. EUCAST definitive document EDef 9.4: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds EDef 9.4. EUCAST-AFST."},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1006\/fgbi.1997.1021"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1309157110"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph15111427"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fgb.2008.08.010"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040343"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-9-402"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.709942"},{"key":"e_1_3_3_46_2","first-page":"E54","article-title":"Characterization of tamoxifen as an antifungal agent using the yeast schizosaccharomyces pombe model organism","volume":"61","author":"Zhang X","year":"2015","unstructured":"Zhang X , Fang Y , Jaiseng W , Hu L , Lu Y , Ma Y , Furuyashiki T . 2015. Characterization of tamoxifen as an antifungal agent using the yeast schizosaccharomyces pombe model organism. Kobe J Med Sci 61:E54\u201363.","journal-title":"Kobe J Med Sci"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00079-20"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03670-22"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt075"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2660(08)60408-3"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2013.02.006"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2017.005"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23051218"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00918-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00918-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T14:07:57Z","timestamp":1700057277000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00918-23"}},"subtitle":[],"editor":[{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,15]]}},"alternative-id":["10.1128\/aac.00918-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.00918-23","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"assertion":[{"value":"2023-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00918-23"}}